Nanopublication

< Home

ID

http://purl.org/np/RALZwlL1TqgP-xvdQv-A6cEyBPxlpE8n1f6MlYHBIhP_o

Formats

.trig | .trig.txt | .jelly | .jelly.txt

Content

@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix this: <http://purl.org/np/RALZwlL1TqgP-xvdQv-A6cEyBPxlpE8n1f6MlYHBIhP_o> .
@prefix sub: <http://purl.org/np/RALZwlL1TqgP-xvdQv-A6cEyBPxlpE8n1f6MlYHBIhP_o#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix orcid: <https://orcid.org/> .
@prefix nkg: <https://w3id.org/neurodkg/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: a np:Nanopublication;
    np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/HP_0007359> schema:possibleTreatment sub:medtherapy .
  
  sub:medtherapy prov:wasDerivedFrom sub:quote;
    schema:drug <http://identifiers.org/drugbank/DB00776>;
    schema:targetPopulation sub:targetpop;
    nkg:indicationType nkg:AdjunctiveTherapy .
  
  sub:quote prov:value "Oxcarbazepine oral suspension is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.";
    prov:wasQuotedFrom <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2515391e-3a88-4226-92e5-f641c8409fe5> .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "UTEeHwYfV6inHkcTx2niWTf7Ohg0EvKibWcmaNMj3Ihdt6p0yT4KiP1ugQM8N7TQQjuPVFGUpRv9fQOyBuq4cQK+AFZYnqJI21Klqou6PhLmHl9MnO4AbKImtxWzY85mKAUSBk1fu/Stn3+g8MzsxUK+trpMUv65C19FOkK6OQo=";
    npx:hasSignatureTarget this: .
  
  this: dcterms:created "2021-04-03T11:32:11.095+02:00"^^xsd:dateTime;
    dcterms:creator orcid:0000-0002-1468-3557;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    nt:wasCreatedFromTemplate <http://purl.org/np/RA64ptuigOfVGfIhpdwWeJnssaHV9jTQCnAm6Pvgrvmos> .
}